EP.83Design of a Phase 2/3 randomized controlled trial of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy amenable to exon 51 skipping
Kathryn R. Wagner(Kennedy Krieger Institute), Michael Panzara, Volker Straub(Newcastle upon Tyne Hospitals NHS Foundation Trust), M. Eagle, Irina Antonijevic(Wave Life Sciences (United States)), E. Niks(Leiden University Medical Center), Melanie Quintana(Berry & Associates (United States)), Xiao Hu(Wave Life Sciences (United States)), Francesco Muntoni(Great Ormond Street Hospital), H. Phan(Rare Disease Therapeutics (United States)), Stephen Lake(Boston University), Linda Cripe(The Ohio State University), Scott Berry(Queen's University)
Cited by 1
Related Papers
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
|The Lancet Neurology|2009|2k
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
|The Lancet Neurology|2009|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980